[en] The arginine vasopressin (AVP) gene is expressed in certain cancers such as breast cancer, where it is believed to act as an autocrine growth factor. However, little is known about the regulation of the AVP protein precursor (proAVP) or AVP-mediated signaling in breast cancer and this study was undertaken to address some of the basic issues. The cultured cell lines examined (Mcf7, Skbr3, BT474, ZR75, Mcf10a) and human breast cancer tissue extract were found to express proAVP mRNA. Western analysis revealed multiple forms of proAVP protein were present in cell lysates, corresponding to those detected in human hypothalamus extracts. Monoclonal antibodies directed against different regions of proAVP bound to intact live Mcf7 and Skbr3 cells. Dexamethasone increased the amount of proAVP-associated glycopeptide (VAG) secreted by Skbr3 cells and a combination of dexamethasone, IBMX and 8br-cAMP increased cellular levels of VAG. Exogenous AVP (1, 10, and 100 nM) elevated phospho-ERK1/2 levels, and increased cell proliferation was observed in the presence of 10 nM AVP. Concurrent treatment with the V1a receptor antagonist SR49059 reduced the effects of AVP on proliferation in Mcf7 cells, and abolished it in Skbr3 cells. Results here show that proAVP components are found at the surface of Skbr3 and Mcf7 cells and are also secreted from these cells. In addition, they show that AVP promotes cancer cell growth, apparently through a V1-type receptor-mediated pathway and subsequent ERK1/2 activation. Thus, strategies for targeting proAVP should be examined for their effectiveness in diagnosing and treating breast cancer.
Disciplines :
Oncology
Author, co-author :
Keegan, B. P.; Dartmouth Medical School, NH, USA > Physiology
Akerman, B. L.; Dartmouth Medical School, NH, USA > Physiology
Pequeux, Christel ; Université de Liège - ULiège > Département des sciences cliniques > Labo de biologie des tumeurs et du développement
North, W. G.; Dartmouth medical School, NH, USA > Physiology
Language :
English
Title :
Provasopressin expression by breast cancer cells: implications for growth and novel treatment strategies
Publication date :
February 2006
Journal title :
Breast Cancer Research and Treatment
ISSN :
0167-6806
eISSN :
1573-7217
Publisher :
Springer, New York, United States - New York
Volume :
95
Issue :
3
Pages :
265-277
Peer reviewed :
Peer Reviewed verified by ORBi
Funders :
F.R.S.-FNRS - Fonds de la Recherche Scientifique [BE] Fonds Léon Fredericq [BE]
North WG, Fay MJ, Du J: All three vasopressin receptor subtypes are expressed by small-cell carcinoma. Adv Exp Med Biol 449: 335-338, 1998
Van Dort C, Zhao P, Parmelee K, Capps B, Poel A, Listenberger L, Kossoris J, Wasilevich B, Murrey D, Clare P, Burnatowska-Hledin M: VACM-1, a cul-5 gene, inhibits cellular growth by a mechanism that involves MAPK and p53 signaling pathways. Am J Physiol Cell Physiol 285: C1386-1396, 2003
de Bree FM, Knight D, Howell L, Murphy D: Sorting of the vasopressin prohormone into the regulated secretory pathway. FEBS Lett 475: 175-180, 2000
de Bree FM: Trafficking of the vasopressin and oxytocin prohormone through the regulated secretory pathway. J Neuroendocrinol 12: 589-594, 2000
de Bree FM, Van Der Kleij AA, Nijenhuis M, Zalm R, Murphy D, Burbach JP: The hormone domain of the vasopressin prohormone is required for the correct prohormone trafficking through the secretory pathway. J Neuroendocrinol 15: 1156-1163, 2003
Barat C, Simpson L, Breslow E: Properties of human vasopressin precursor constructs: inefficient monomer folding in the absence of copeptin as a potential contributor to diabetes insipidus. Biochemistry 43: 8191-8203, 2004
Iwasaki Y, Oiso Y, Saito H, Majzoub JA: Effects of various mutations in the neurophysin/glycopeptide portion of the vasopressin gene on vasopressin expression in vitro. Tohoku J Exp Med 191: 187-202, 2000
Friedmann AS, Memoli VA, North WG: Vasopressin and oxytocin production by non-neuroendocrine lung carcinomas: an apparent low incidence of gene expression. Cancer Lett 75: 79-85, 1993
Taylor AH, Ang VT, Jenkins JS, Silverlight JJ, Coombes RC, Luqmani YA: Interaction of vasopressin and oxytocin with human breast carcinoma cells. Cancer Res 50: 7882-7886, 1990
Nilsson H, Eriksson LC: Growth factor induced mitogenic effects and inositol phosphate responses in primary hepatocyte cultures from normal rat liver and rat liver nodules. Carcinogenesis 15: 1821-1826, 1994
Schwindt TT, Forti FL, Juliano MA, Juliano L, Armelin HA: Arginine vasopressin inhibition of cyclin D1 gene expression blocks the cell cycle and cell proliferation in the mouse Y1 adrenocortical tumor cell line. Biochemistry 42: 2116-2121, 2003
Seckl MJ, Higgins T, Widmer F, Rozengurt E: [D-Arg1,D-Trp5,7,9,Leul1] substance P: a novel potent inhibitor of signal transduction and growth in vitro and in vivo in small cell lung cancer cells. Cancer Res 57: 51-54, 1997
Yamaguchi T, Pelling JC, Ramaswamy NT, Eppler JW, Wallace DP, Nagao S, Rome LA, Sullivan LP, Grantham JJ: cAMP stimulates the in vitro proliferation of renal cyst epithelial cells by activating the extracellular signal-regulated kinase pathway. Kidney Int 57: 1460-1471, 2000
North WG, Fay MJ, Du J: MCF-7 breast cancer cells express normal forms of all vasopressin receptors plus an abnormal V2R. Peptides 20: 837-842, 1999
North WG, Fay MJ, Longo KA, Du J: Expression of all known vasopressin receptor subtypes by small cell tumors implies a multifaceted role for this neuropeptide. Cancer Res 58: 1866-1871, 1998
Giron S, Tejera AM, Ripoll GV, Gomez DE, Alonso DF: Desmopressin inhibits lung and lymph node metastasis in a mouse mammary carcinoma model of surgical manipulation. J Surg Oncol 81: 38-44, 2002
Pequeux C, Keegan BP, Hagelstein MT, Geenen V, Legros JJ, North WG: Oxytocin- and vasopressin-induced growth of human small-cell lung cancer is mediated by the mitogen-activated protein kinase pathway. Endocr Relat Cancer 11: 871-885, 2004
Verbeeck MA, Sutanto W, Burbach JP: Regulation of vasopressin messenger RNA levels in the small cell lung carcinoma cell line GLC-8: interactions between glucocorticoids and second messengers. Mol Endocrinol 5: 795-801, 1991
Friedmann AS, Fay MJ, Memoli VA, North WG: Factors regulating the production of vasopressin-associated human neurophysin by small-cell carcinoma of the lung: evaluation by computer-enhanced quantitative immunocytochemistry. Neuropeptides 28: 183-189, 1995
Coulson JM: Positive and negative regulators of the vasopressin gene promoter in small cell lung cancer. Prog Brain Res 139: 329-343, 2002
Coulson JM, Edgson JL, Marshall-Jones ZV, Mulgrew R, Quinn JP, Woll PJ: Upstream stimulatory factor activates the vasopressin promoter via multiple motifs, including a non-canonical E-box. Biochem J 369: 549-561, 2003
Coulson JM, Fiskerstrand CE, Woll PJ, Quinn JP: E-box motifs within the human vasopressin gene promoter contribute to a major enhancer in small-cell lung cancer. Biochem J 344 Pt 3: 961-970, 1999
Coulson JM, Fiskerstrand CE, Woll PJ, Quinn JP: Arginine vasopressin promoter regulation is mediated by a neuron-restrictive silencer element in small cell lung cancer. Cancer Res 59: 5123-5127, 1999
Coulson JM, Stanley J, Woll PJ: Tumour-specific arginine vasopressin promoter activation in small-cell lung cancer. Br J Cancer 80: 1935-1944, 1999
Coulson JM, Edgson JL, Woll PJ, Quinn JP: A splice variant of the neuron-restrictive silencer factor repressor is expressed in small cell lung cancer: a potential role in derepression of neuroendocrine genes and a useful clinical marker. Cancer Res 60: 1840-1844, 2000
Keegan BP, Memoli VA, North WG: Targeting the neurophysin-related cell surface antigen on small cell lung cancer cells using a monoclonal antibody against the glycopeptide region (MAG-1) of provasopressin. Mol Cancer Ther 1: 1153-1159, 2002
North WG, Yu XM: Vasopressin mRNA and neurophysin-related cell-surface antigen (NRSA) in small-cell carcinoma. Peptides 14: 303-307, 1993
North WG, Wells W, Fay MJ, Mathew RS, Donnelly EM, Memoli VA: Immunohistochemical evaluation of vasopressin expression in breast fibrocystic disease and ductal carcinoma in situ (DCIS). Endocr Pathol 14: 257-262, 2003
North WG, Pai S, Friedmann A, Yu X, Fay M, Memoli V: Vasopressin gene related products are markers of human breast cancer [published erratum appears in Breast Cancer Res Treat 1995;36(1):99]. Breast Cancer Res Treat 34: 229-235, 1995
Terasaki T, Matsuno Y, Shimosato Y, Yamaguchi K, Ichinose H, Nagatsu T, Kato K: Establishment of a human small cell lung cancer cell line producing a large amount of anti-diuretic hormone. Jpn J Cancer Res 85: 718-722, 1994
North WG, LaRochelle FT, Jr., Haldar J, Sawyer WH, Valtin H: Characterization of an antiserum used in a radioimmunoassay for arginine-vasopressin: implications for reference standards. Endocrinology 103: 1976-1984, 1978
Maggiolini M, Vivacqua A, Fasanella G, Recchia AG, Sisci D, Pezzi V, Montanaro D, Musti AM, Picard D, Ando S: The G protein-coupled receptor GPR30 mediates c-fos up-regulation by 17beta-estradiol and phytoestrogens in breast cancer cells. J Biol Chem 279: 27008-27016, 2004
Beguin P, Nicolas P, Boussetta H, Fahy C, Cohen P: Characterization of the 80,000 molecular weight form of neurophysin isolated from bovine neurohypophysis. J Biol Chem 256: 9289-9294, 1981
North WG, Maurer H, O'Donnell JF: The neurophysins and small cell lung cancer. In: Greco F. Martinus (ed.), Biology and Management of Lung Cancer. Nijhoff, Boston, 1983, pp. 143-169
North WG, Yu X: Forms of neurohypophysial peptides generated by tumors, and factors regulating their expression. Regul Pept 45: 209-216, 1993
Alonso DF, Skilton G, Farias EF, de Bal Kier Joffe E, Gomez DE: Antimetastatic effect of desmopressin in a mouse mammary tumor model. Breast Cancer Res Treat 57: 271-275, 1999
Soule HD, Maloney TM, Wolman SR, Peterson WD, Jr., Brenz R, McGrath CM, Russo J, Pauley RJ, Jones RF, Brooks SC: Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. Cancer Res 50: 6075-6086, 1990
Khanuja PS, Lehr JE, Soule HD, Gehani SK, Noto AC, Choudhury S, Chen R, Pienta KJ: Nuclear matrix proteins in normal and breast cancer cells. Cancer Res 53: 3394-3398, 1993
Mackinnon AC, Tufail-Hanif U, Lucas CD, Jodrell D, Haslett C, Sethi T: Expression of V(1A) and GRP receptors leads to cellular transformation and increased sensitivity to substance-P analogue-induced growth inhibition. Br J Cancer 92: 522-531, 2005
Zhao JJ, Gjoerup OV, Subramanian RR, Cheng Y, Chen W, Roberts TM, Hahn WC: Human mammary epithelial cell transformation through the activation of phosphatidylinositol 3-kinase. Cancer Cell 3: 483-495, 2003
Nicolas P, Camier M, Lauber M, Masse MJ, Mohring J, Cohen P: Immunological identification of high molecular weight forms common to bovine neurophysin and vasopressin. Proc Natl Acad Sci USA 77: 2587-2591, 1980
Moore GJ, Rosenior JC: Characterization of the "giant precursors" (70-80 K) of vasopressin and oxytocin in the rat hypothalamus. Prog Brain Res 60: 253-256, 1983
Rosenior JC, North WG, Moore GJ: Biosynthesis of oxytocin and oxytocin-neurophysin in homozygous Brattleboro rats. Ann N Y Acad Sci 394: 183-187, 1982
Camier M, Lauber M, Mohring J, Cohen P: Evidence for higher molecular weight immunoreactive forms of vasopressin in the mouse hypothalamus. Relationships with putative proneurophysins. FEBS Lett 108: 369-373, 1979
Lauber M, Camier M, Cohen P: Immunological and biochemical characterization of distinct high molecular weight forms of neurophysin and somatostatin in mouse hypothalamus extracts. FEBS Lett 97: 343-347, 1979
Verbalis JG, Robinson AG: Characterization of neurophysin-vasopressin prohormones in human posterior pituitary tissue. J Clin Endocrinol Metab 57: 115-123, 1983
Friberg MA, Spiess M, Rutishauser J: Degradation of wild-type vasopressin precursor and pathogenic mutants by the proteasome. J Biol Chem 279: 19441-19447, 2004
Starzec AB, Spanakis E, Nehme A, Salle V, Veber N, Mainguene C, Planchon P, Valette A, Prevost G, Israel L: Proliferative responses of epithelial cells to 8-bromo-cyclic AMP and to a Phorbol ester change during breast pathogenesis. J. Cell Physiol 161: 31-38, 1994
Song Z, Sidorowicz HE, Sladek CD: cAMP stimulation of vasopressin and oxytocin release and regulation of vasopressin mRNA stability: role of auto-facilitation. J Neuroendocrinol 13: 158-165, 2001
Erkut ZA, Gabreels BA, Eikelenboom J, van Leeuwen FW, Swaab DF: Glucocorticoid treatment is associated with decreased expression of processed AVP but not of proAVP, neurophysin or oxytocin in the human hypothalamus: are PC1 and PC2 involved? Neuroendocrinol Lett 23: 33-44, 2002
Cwikel BJ, Habener JF: Provasopressin-neurophysin II processing is cell-specific in heterologous cell lines expressing a metallothionein- vasopressin fusion gene. J Biol Chem 262: 14235-14240, 1987
Andersen MK, Sorensen JB: Development of syndrome of inappropriate secretion of antidiuretic hormone during progression of metastatic breast cancer. Acta Oncol 36: 535-537, 1997
Howard AC, Laing RW, Hussain FN: Breast carcinoma presenting with inappropriate ADH secretion. Eur J Cancer 29A: 2339, 1993
Gupta A, Sasarula S, Rao PV: The syndrome of inappropriate secretion of antidiuretic hormone in a case of carcinoma of the breast. J Assoc Physicians India 34: 441-442, 1986
Du J, Keegan BP, North WG: Key peptide processing enzymes are expressed by breast cancer cells. Cancer Lett 165: 211-218, 2001
Seufferlein T, Rozengurt E: Galanin, neurotensin, and phorbol esters rapidly stimulate activation of mitogen-activated protein kinase in small cell lung cancer cells. Cancer Res 56: 5758-5764, 1996
Chiu T, Wu SS, Santiskulvong C, Tangkijvanich P, Yee HF Jr., Rozengurt E Vasopressin-mediated mitogenic signaling in intestinal epithelial cells. Am J Physiol Cell Physiol 282: C434-450, 2002
Thibonnier M, Conarty DM, Plesnicher CL: Mediators of the mitogenic action of human V(1) vascular vasopressin receptors. Am J Physiol Heart Circ Physiol 279: H2529-2539, 2000
Gilad L, Bresler T, Gnainsky J, Smirnoff P, Schwartz B: Regulation of vitamin D receptor expression via estrogen-induced activation of the ERK 1/2 signaling pathway in colon and breast cancer cells. J Endocrinol 185: 577, 2005
Lu Y, Zi X, Zhao Y, Pollak M: Overexpression of ErbB2 receptor inhibits IGF-I-induced Shc-MAPK signaling pathway in breast cancer cells. Biochem Biophys Res Commun 313: 709-715, 2004
Zivadinovic D, Watson C: Membrane estrogen receptor-alpha levels predict estrogen-induced ERK1/2 activation in MCF-7 cells. Breast Cancer Res 7: R130-R144, 2005
Folny V, Raufaste D, Lukovic L, Pouzet B, Rochard P, Pascal M, Serradeil-Le Gal C: Pancreatic vasopressin V1b receptors: characterization in In-R1-G9 cells and localization in human pancreas. Am J Physiol Endocrinol Metab 285: E566-576, 2003
Bunn PA, Jr., Dienhart DG, Chan D, Tagawa M, Jewett P: Effects of neuropeptides on human lung and breast cancer cells. J Natl Cancer Inst Monogr : 145-151, 1992
